This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Lundbeck licenses two Teva Parkinson's disease drugs
Danish CNS drug developer H. Lundbeck in collaboration with Teva (Israel's largest pharmaceutical company), will co-develop the latter's Parkinson's disease drugs: the Phase III Rasagiline and TV 1203, in Phase II. Lundbeck will get exclusive European marketing rights from Teva, which will retain rights in all other territories worldwide.
R+D and Marketing-Licensing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?